BRCA BROS
Back to what men should know

Emerging research

New results show up constantly and most of them get oversold. Every entry here says plainly how solid the evidence is, so an early study never gets mistaken for medical advice.

Supports current guidelines means the finding backs what major guidelines already recommend. Under FDA review means a decision is still pending. Not studied in BRCA carriers means the research exists in other groups, but nobody has tested it in people with these mutations. Approved for advanced cancer means a drug the FDA has cleared for men who already have the disease, not a way to prevent it.

Last reviewed November 2026.

Supports current guidelines

Annual PSA screening finds more serious prostate cancer in BRCA2 carriers

The IMPACT study followed more than 1,800 BRCA1 and BRCA2 carriers, plus a comparison group of non-carriers, across 20 countries. Everyone got a PSA blood test every year for five years, with a biopsy if the number went above 3.0 ng/mL.[1]IMPACT study five-year results, European Urology, 2026

After five rounds, BRCA2 carriers were diagnosed with clinically significant prostate cancer more than twice as often as non-carriers, 3.1% versus 1.3%. Among the cancers that were found, 65% in BRCA2 carriers were intermediate-unfavorable or high risk, compared with 32% in non-carriers. None had spread at diagnosis. For BRCA1 carriers, the difference in clinically significant cancer wasn't statistically significant, and the authors say screening should be considered rather than recommended outright.[1]IMPACT study five-year results, European Urology, 2026

One limit worth knowing: the study began in 2005, before prostate MRI became part of the diagnostic process, so it tells us about PSA screening and nothing about MRI.

Bottom line: this lines up with the current NCCN guidance of annual PSA screening starting at 40 for BRCA2 carriers.[2]NCCN Guidelines Insights 2026: Genetic/Familial High-Risk Assessment If you carry a mutation and haven't brought it up with your doctor yet, this is a good study to bring with you. Your ages are on the When to screen page.

Under FDA review, not approved

One blood test that looks for many cancers

Multi-cancer early detection tests look for signs of cancer in a blood sample. The best known, Galleri, is designed for adults 50 and older as an add-on to regular screening, not a replacement for it.[3]Targeted Oncology: FDA Panel Votes in Favor of Galleri

The big test of the idea was NHS-Galleri, a trial of about 142,000 people in England. It missed its main goal: adding the test did not significantly reduce the number of stage III and IV cancers (rate ratio 1.03, confidence interval 0.92 to 1.14). Stage IV cancers were numerically lower (0.86), but the interval reaches 1.00, so it isn't counted as a significant drop.[4]NHS-Galleri, New England Journal of Medicine, 2026

In late September an FDA advisory panel voted 7 to 2, with one abstention, that the benefits outweigh the risks. The vote on whether the test works was closer, 6 to 4. The considerations included lower sensitivity for breast and prostate cancers, and the fact that nearly three in four people with a positive signal had at least one invasive procedure. The FDA hasn't made a final decision.[3]Targeted Oncology: FDA Panel Votes in Favor of Galleri

Bottom line: an interesting idea with a benefit that hasn't been shown yet, and less sensitive for two of the cancers male carriers worry about most, breast and prostate. It doesn't replace the screening on the When to screen page.

Not studied in BRCA carriers

Aspirin

Aspirin shows up on a lot of cancer prevention lists, so here is what the evidence actually covers. The strongest result comes from Lynch syndrome, a different inherited condition. In the CAPP2 trial, 861 Lynch syndrome carriers took aspirin or a placebo, and long-term follow-up showed a lower rate of colorectal cancer in the aspirin group (hazard ratio 0.65). It showed no effect on the other cancers Lynch syndrome causes.[5]CAPP2 trial, The Lancet, 2020

We didn't find a trial testing aspirin for cancer prevention in people with BRCA mutations. Aspirin also raises the risk of serious bleeding, which is why guidelines treat it as a decision to make with a doctor and not a default.[6]U.S. Preventive Services Task Force: Aspirin Use to Prevent Cardiovascular Disease

Bottom line: a BRCA result alone isn't a reason to start taking aspirin. If the question interests you, bring it to your doctor, who can weigh it against your own bleeding risk.

Approved for advanced cancer, not prevention

PARP inhibitors: medication for men who already have prostate cancer

PARP inhibitors are pills that go after cancer cells with faulty DNA repair, which is exactly what a BRCA mutation causes. They are treatments for men whose prostate cancer has already spread. We didn't find any trial or approval for using them to prevent cancer in healthy carriers.

The FDA has approved two combinations as first-line treatment for advanced, castration-resistant prostate cancer: olaparib with abiraterone (May 2023, for BRCA-mutated disease) and talazoparib with enzalutamide (June 2023, for disease with a DNA-repair gene mutation). In the talazoparib trial, the risk of the cancer progressing on scans or of death was cut by more than half in men with those mutations (hazard ratio 0.45).[7]FDA Approval Summary: talazoparib plus enzalutamide, Journal of Clinical Oncology, 2024

Newer results push the idea earlier. In TALAPRO-3, published in the New England Journal of Medicine this year, adding talazoparib to enzalutamide and hormone therapy in men with DNA-repair mutations raised the share alive without progression at three years from 56% to 77%. Overall survival was not significantly different yet, and serious side effects were more common, 42% versus 32%. We didn't find an FDA approval for that earlier use.[8]TALAPRO-3, New England Journal of Medicine, 2026

In BRCAAway, a small phase 2 trial of 61 men with BRCA1, BRCA2 or ATM changes, median time before progression was 8.6 months with abiraterone, 14 months with olaparib, and 39 months with both together. Small phase 2 results like these are promising, not proof.[9]BRCAAway, Clinical Cancer Research, 2024

One trial worth watching for carriers: EvoPAR-Prostate02 is testing the newer PARP inhibitor saruparib after radiation in men with BRCA-mutated, high-risk prostate cancer that hasn't spread. It is still enrolling and has no results.[10]ClinicalTrials.gov NCT06952803, EvoPAR-Prostate02

Bottom line: a BRCA result can change which drugs are used if prostate cancer ever shows up, which is another reason to know your status. It is not a reason to take anything now. If you do have advanced prostate cancer, ask your oncologist whether your mutation affects your options.

Something you want looked at? Email hello@brcabros.com.

This page is general information, not medical advice.

  1. [1] Targeted prostate cancer screening in BRCA1 or BRCA2 pathogenic germline variant carriers detects clinically relevant disease: five-year results of the IMPACT study, European Urology, 2026
  2. [2] NCCN Guidelines Insights 2026: Genetic/Familial High-Risk Assessment
  3. [3] Targeted Oncology: FDA Panel Votes in Favor of Galleri Multi-Cancer Early Detection Test
  4. [4] Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis (NHS-Galleri), New England Journal of Medicine, 2026
  5. [5] Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study, The Lancet, 2020
  6. [6] U.S. Preventive Services Task Force: Aspirin Use to Prevent Cardiovascular Disease
  7. [7] FDA Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer, Journal of Clinical Oncology, 2024 (also notes the May 2023 olaparib plus abiraterone approval)
  8. [8] PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer (TALAPRO-3), New England Journal of Medicine, 2026
  9. [9] Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway), Clinical Cancer Research, 2024
  10. [10] ClinicalTrials.gov: saruparib vs placebo added to radiotherapy and ADT in high-risk prostate cancer with a BRCA mutation (EvoPAR-Prostate02, NCT06952803)